61940-21-4

Basic information

• Product Name: METHYL 2-BROMOMETHYL-6-NITRO-BENZOATE
• Synonyms: METHYL 2-BROMOMETHYL-6-NITRO-BENZOATE;Benzoic acid, 2-(bromomethyl)-6-nitro-, methyl ester;2-BroMoMethyl-6-nitrobenzoic Acid Methyl Ester;-6-nitrobenzoate;Lenalidomide Impurity 18
• CAS NO: 61940-21-4
• Molecular Formula: C₉H₈BrNO₄
• Molecular Weight: 274.07
• Mol File: 61940-21-4.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: METHYL 2-BROMOMETHYL-6-NITRO-BENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-BROMOMETHYL-6-NITRO-BENZOATE(61940-21-4)
• EPA Substance Registry System: METHYL 2-BROMOMETHYL-6-NITRO-BENZOATE(61940-21-4)

Safety Data

• Hazardous Substances Data: 61940-21-4(Hazardous Substances Data)

Usage

Uses

2-Bromomethyl-6-nitrobenzoic Acid Methyl Ester is a potential cyclooxygenase inhibitor derived from thalidomide (T338850), an immunomodulatory agent used primarily in combination with dexamethasone to treat multiple myeloma.

InChI:InChI:1S/C9H8BrNO4/c1-15-9(12)8-6(5-10)3-2-4-7(8)11(13)14/h2-4H,5H2,1H3

Upstream product

• 61940-22-5 methyl 2-methyl-6-nitrobenzoate 
• 94-36-0 dibenzoyl peroxide 
• 13506-76-8 2-methyl-6-nitrobenzoic acid 

Downstream Products

• 878156-03-7 methyl 2-(dimethylphosphonomethyl)-6-nitrobenzoate 
• 169044-99-9 methyl 2-(cyanomethyl)-6-nitrobenzoate 
• 959737-79-2 2-(cyclohexylmethyl)-7-nitroisoindolin-1-one 
• 651733-80-1 2-(3,5-dimethyl-phenyl)-7-nitro-2,3-dihydro-isoindol-1-one 
• 878155-22-7 8-amino-2-methyl-3,4-dihydroisoquinolin-1-one 
• 878156-33-3 8-dibenzylamino-3,4-dihydro-2H-isoquinolin-1-one 
• 169045-00-5 8-amino-3,4-dihydro-2H-isoquinolin-1-one 
• 1015474-89-1 2-(di-tert-butoxycarbonylamino-methyl)-6-nitro-benzoic acid methyl ester 
• 959737-80-5 7-amino-2-(cyclohexylmethyl)isoindolin-1-one 
• 61940-27-0 N-[2-(α-methoxymethyl)-6-nitrobenzyl]-glycine ethyl ester 
• 61940-24-7 2-(α-methoxymethyl)-6-nitrobenzoic acid 

Relevant articles and documents

CHEMICAL COMPOUNDS

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.

NOVEL PIPERIDINE-2,6-DIONE DERIVATIVE AND USE THEREOF

The present disclosure relates to a novel piperidine-2,6-dione derivative and a use thereof and, more specifically, to a piperidine-2,6-dione derivative compound having a structure of a thalidomide analog. A compound of chemical formula 1 according to the present disclosure specifically binds with CRBN protein, and is involved in functions thereof. Therefore, the compound of the present disclosure can be favorably used in the prevention or treatment of leprosy, chronic graft versus host disease, an inflammatory disease, or cancer, which are caused by actions of CRBN protein.

Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases

Methods of treating, preventing, or managing autoimmune inflammatory diseases and disorders including but not limited to spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, osteoarthritis, ankylosing spondylitis, and rheumatoid arthritis by the administration of phosphodiesterase 4 (PDE4) inhibitors in combination with other therapeutics are disclosed. Pharmaceutical compositions, dosage forms, and kits suitable for use in methods of the invention are also disclosed.